Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

ClinicalTrials.gov ID: NCT02234843

Public ClinicalTrials.gov record NCT02234843. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of an age-and Body Weight-adjusted Rivaroxaban Regimen Compared to Standard of Care in Children With Acute Venous Thromboembolism

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate comparative efficacy and safety of rivaroxaban to standard of care in children with acute venous thromboembolism.

Study identification

NCT ID
NCT02234843
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bayer
Industry
Enrollment
500 participants

Conditions and interventions

Eligibility (public fields only)

Age range
Up to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 12, 2014
Primary completion
Jan 29, 2019
Completion
Jan 29, 2019
Last update posted
Mar 31, 2020

2014 – 2019

United States locations

U.S. sites
23
U.S. states
13
U.S. cities
22
Facility City State ZIP Site status
Not listed Phoenix Arizona 85016
Not listed Little Rock Arkansas 72202-3500
Not listed Los Angeles California 90027-6089
Not listed Los Angeles California 90095
Not listed San Diego California 92123
Not listed Gainesville Florida 32610
Not listed Jacksonville Florida 32207
Not listed Miami Florida 33155
Not listed Pensacola Florida 32504
Not listed St. Petersburg Florida 33701
Not listed Atlanta Georgia 30322
Not listed Chicago Illinois 60611
Not listed Indianapolis Indiana 46202
Not listed Lansing Michigan 48912
Not listed Kansas City Missouri 64108-9898
Not listed Durham North Carolina 27710
Not listed Cincinnati Ohio 45229-3039
Not listed Cleveland Ohio 44106-2602
Not listed Columbus Ohio 43205-2696
Not listed Philadelphia Pennsylvania 19104
Not listed Dallas Texas 75235
Not listed Fort Worth Texas 76104
Not listed Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 86 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02234843, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 31, 2020 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02234843 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →